Patent SG-11201900461U-A (SG)
Title: Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
Inventor: LOUMAYE ERNEST
IPC: A61P5/10
Filed: 2017-07-20
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111 0 1110101011111 011101 0 0111111111 100 1111111011111111110 111 0111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/015497 A3 25 January 2018 (25.01.2018) WI P0 I P C T (51) International Patent Classification: A61K 31/40 (2006.01) A61P 5/10 (2006.01) Published: — with international search report (Art. 2 1 (3)) (21) International Application Number: — before the expiration of the time limit for amending the PCT/EP2017/068378 claims and to be republished in the event of receipt of (22) International Filing Date: amendments (Rule 48.2(h)) 20 July 2017 (20.07.2017) (88) Date of publication of the international search report: 01 March 2018 (01.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/365,147 21 July 2016 (21.07.2016) US 62/527,721 30 June 2017 (30.06.2017) US (71) Applicant: OBSEVA S.A. [CH/CH]; Chemin des Aulx 12, 1228 Plan-les-Ouates (CH). (72) Inventors: LOUMAYE, Ernest; 29 Chemin de la Planta, 1223 Cologny (CH). GOTTELAND, Jean-Pierre; 9 Rue Charles Humbert, 1205 Geneva (CH). Agent: KATZAROV S.A.; Rue des Epinettes 19, 1227 (74) Geneva (CH). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (84) M IN ON (54) Title: OXYTOCIN ANTAGONIST DOSING REGIMENS FOR PROMOTING EMBRYO IMPLANTATION AND PREVEN- 7 r TING MISCARRIAGE ir) Il (57) : The invention provides compositions and methods for the use of oxytocin antagonists, such as substituted pyrro- 0 ---- lidin-3-one oxime derivatives, among other compounds, in the treatment of subjects undergoing embryo transfer therapy. The composi- GC tions and methods of the invention can be used to dose subjects with oxytocin antagonists, including (3Z,55)-5-(hydroxymethyl)-1-[(2'- 1-1 © methyl-1,1'-biphenyl- 4-yl)carbonyl]pyrrolidin-3-one 0-methyloxime, among others, so as to improve endometrial receptivity and re- f'1 duce the likelihood of embryo implantation failure and miscarriage following, for example, in vitro fertilization (IVF) and intracyto- C plasmic sperm injection (ICSI) embryo transfer procedures.